Literature DB >> 9234682

Efficient repression of endogenous major histocompatibility complex class II expression through dominant negative CIITA mutants isolated by a functional selection strategy.

S Bontron1, C Ucla, B Mach, V Steimle.   

Abstract

Major histocompatibility complex class II (MHC-II) molecules present peptide antigens to CD4-positive T cells and are of critical importance for the immune response. The MHC-II transactivator CIITA is essential for all aspects of MHC-II gene expression examined so far and thus constitutes a master regulator of MHC-II expression. In this study, we generated and analyzed mutant CIITA molecules which are able to suppress endogenous MHC-II expression in a dominant negative manner for both constitutive and inducible MHC-II expression. Dominant negative CIITA mutants were generated via specific restriction sites and by functional selection from a library of random N-terminal CIITA deletions. This functional selection strategy was very effective, leading to strong dominant negative CIITA mutants in which the N-terminal acidic and proline/serine/threonine-rich regions were completely deleted. Dominant negative activity is dependent on an intact C terminus. Efficient repression of endogenous MHC-II mRNA levels was quantified by RNase protection analysis. The quantitative effects of various dominant negative CIITA mutants on mRNA expression levels of the different MHC-II isotypes are very similar. The optimized dominant negative CIITA mutants isolated by functional selection should be useful for in vivo repression of MHC-II expression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9234682      PMCID: PMC232278          DOI: 10.1128/MCB.17.8.4249

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  43 in total

1.  SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat.

Authors:  Y Takebe; M Seiki; J Fujisawa; P Hoy; K Yokota; K Arai; M Yoshida; N Arai
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

Review 2.  Functional inactivation of genes by dominant negative mutations.

Authors:  I Herskowitz
Journal:  Nature       Date:  1987 Sep 17-23       Impact factor: 49.962

3.  Analysis by sequential immunoprecipitations of the specificities of the monoclonal antibodies TU22,34,35,36,37,39,43,58 and YD1/63.HLK directed against human HLA class II antigens.

Authors:  A Ziegler; J Heinig; C Müller; H Götz; F P Thinnes; B Uchańska-Ziegler; P Wernet
Journal:  Immunobiology       Date:  1986-03       Impact factor: 3.144

4.  Differential presentation of HLA-DR, DQ, and DP restriction elements by interferon-gamma-treated dermal fibroblasts.

Authors:  D H Maurer; J H Hanke; E Mickelson; R R Rich; M S Pollack
Journal:  J Immunol       Date:  1987-08-01       Impact factor: 5.422

5.  Two novel mutations in the MHC class II transactivator CIITA in a second patient from MHC class II deficiency complementation group A.

Authors:  S Bontron; V Steimle; C Ucla; M M Eibl; B Mach
Journal:  Hum Genet       Date:  1997-04       Impact factor: 4.132

6.  A eukaryotic transcriptional activator bearing the DNA specificity of a prokaryotic repressor.

Authors:  R Brent; M Ptashne
Journal:  Cell       Date:  1985-12       Impact factor: 41.582

7.  Congenital immunodeficiency with a regulatory defect in MHC class II gene expression lacks a specific HLA-DR promoter binding protein, RF-X.

Authors:  W Reith; S Satola; C H Sanchez; I Amaldi; B Lisowska-Grospierre; C Griscelli; M R Hadam; B Mach
Journal:  Cell       Date:  1988-06-17       Impact factor: 41.582

8.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis.

Authors:  C J Barnstable; W F Bodmer; G Brown; G Galfre; C Milstein; A F Williams; A Ziegler
Journal:  Cell       Date:  1978-05       Impact factor: 41.582

9.  Detection of a novel human class II HLA antigen.

Authors:  A J Watson; R DeMars; I S Trowbridge; F H Bach
Journal:  Nature       Date:  1983 Jul 28-Aug 3       Impact factor: 49.962

10.  A bacteriophage T7 RNA polymerase/promoter system for controlled exclusive expression of specific genes.

Authors:  S Tabor; C C Richardson
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

View more
  26 in total

1.  CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex.

Authors:  K Masternak; A Muhlethaler-Mottet; J Villard; M Zufferey; V Steimle; W Reith
Journal:  Genes Dev       Date:  2000-05-01       Impact factor: 11.361

Review 2.  Class II transactivator: mastering the art of major histocompatibility complex expression.

Authors:  J A Harton; J P Ting
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

3.  Downregulation of CIITA function by protein kinase a (PKA)-mediated phosphorylation: mechanism of prostaglandin E, cyclic AMP, and PKA inhibition of class II major histocompatibility complex expression in monocytic lines.

Authors:  G Li; J A Harton; X Zhu; J P Ting
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

4.  Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation.

Authors:  Krzysztof Masternak; Walter Reith
Journal:  EMBO J       Date:  2002-03-15       Impact factor: 11.598

5.  Expression of the three human major histocompatibility complex class II isotypes exhibits a differential dependence on the transcription factor RFXAP.

Authors:  M Peretti; J Villard; E Barras; M Zufferey; W Reith
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

6.  CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation.

Authors:  S B Hake; K Masternak; C Kammerbauer; C Janzen; W Reith; V Steimle
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

Review 7.  Novel mechanisms of class II major histocompatibility complex gene regulation.

Authors:  Michael Radosevich; Santa Jeremy Ono
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

8.  New functions of the major histocompatibility complex class II-specific transcription factor RFXANK revealed by a high-resolution mutagenesis study.

Authors:  Michal Krawczyk; Krzysztof Masternak; Madeleine Zufferey; Emmanuèle Barras; Walter Reith
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

9.  Targeting of the Sendai virus C protein to the plasma membrane via a peptide-only membrane anchor.

Authors:  Jean-Baptiste Marq; Albert Brini; Daniel Kolakofsky; Dominique Garcin
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

10.  The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element.

Authors:  J A Brown; E M Rogers; J M Boss
Journal:  Nucleic Acids Res       Date:  1998-09-15       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.